Researchers Urge Renaming Polycystic Ovary Syndrome to Better Reflect the Condition

A new global proposal is asking clinicians and researchers to rename polycystic ovary syndrome (PCOS) to polyendocrine metabolic ovarian syndrome (PMOS), arguing that the current label understates the disorder’s body-wide effects. PCOS affects an estimated 170 million adolescents and women worldwide, yet its name historically points primarily to the ovaries rather than to the endocrine and metabolic networks involved.

The rationale comes from a recent The Lancet paper describing a multistep consensus process. The proposal centers on a refined understanding: PMOS is not only a reproductive condition, but also a complex hormonal and metabolic syndrome with long-term health consequences that span far beyond fertility outcomes.

Heidi Vanden Brink, Ph.D., a reproductive physiologist at Texas A&M, emphasizes that the proposed PMOS framework better reflects what patients experience. According to her, living with PMOS can involve reproductive, metabolic, and psychological burdens, and these are often overlooked when the condition is framed as primarily “ovarian.”

Clinically, PMOS is believed to affect roughly one in eight women. In Texas, reported diagnoses reach up to 15% (about one in seven). Brink notes that many people are misdiagnosed or remain undiagnosed—particularly when symptoms are dismissed or attributed to unrelated causes.

The syndrome is diagnosed using a “two-out-of-three” approach after excluding alternative disorders. The features include irregular menstrual cycles, biochemical or clinical evidence of elevated testosterone, and either polycystic-appearing ovaries (in the specific follicle-count sense) or elevated anti-Müllerian hormone (AMH), a marker produced by ovarian follicles.

Importantly, the term “polycystic ovaries” can mislead. In PMOS, it refers to a higher number of smaller, fluid-filled follicles rather than the large cysts commonly imagined by the public. This nuance matters because misunderstanding the diagnostic criteria can delay recognition and appropriate care.

PMOS also intersects strongly with metabolic risk, including insulin resistance and elevated chances of type 2 diabetes, cardiovascular disease, and liver-related conditions. Psychological health may be affected as well, with anxiety, depression, and reduced quality of life reported in association with the syndrome.

For adolescents, the name change may be particularly consequential. Melanie Cree, M.D., Ph.D., highlights that puberty can alter metabolic labs, and that ovary-based criteria are less used in teen diagnosis—so communication that still revolves around “ovaries” can confuse families when clinicians are actually tracking metabolic complications.

By shifting the emphasis from fertility alone toward endocrine-metabolic regulation, the proposed PMOS label aims to improve awareness, support multidisciplinary management, and help address underdiagnosis through clearer, more patient-relevant messaging. The Lancet paper also advances the idea that coordinated interventions may lead to earlier identification and better long-term outcomes.